<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, diagnosis, and treatment of plague (&lt;i&gt;Yersinia pestis&lt;/i&gt; infection)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, diagnosis, and treatment of plague (
       <i>
        Yersinia pestis
       </i>
       infection)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, diagnosis, and treatment of plague (
        <i>
         Yersinia pestis
        </i>
        infection)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason Stout, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the genus
         <em>
          Yersinia
         </em>
         , three species are important human pathogens:
         <em>
          Yersinia pestis
         </em>
         ,
         <em>
          Yersinia enterocolitica
         </em>
         , and
         <em>
          Yersinia pseudotuberculosis
         </em>
         . The yersinioses are zoonotic infections of domestic and wild animals; humans are considered incidental hosts that do not contribute to the natural disease cycle.
        </p>
        <p>
         <em>
          Y. pestis
         </em>
         causes plague and is transmitted by fleas. The most common clinical manifestation is acute febrile lymphadenitis, called bubonic plague. Less common forms include septicemia, pneumonia, pharyngeal, and meningeal plague.
        </p>
        <p>
         The clinical features, diagnosis, and treatment of plague will be reviewed here. The epidemiology, microbiology, and pathogenesis of
         <em>
          Y. pestis
         </em>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3143.html" rel="external">
          "Epidemiology, microbiology and pathogenesis of plague (
          <i>
           Yersinia pestis
          </i>
          infection)"
         </a>
         .)
        </p>
        <p>
         Issues related to other
         <em>
          Yersinia
         </em>
         species are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3139.html" rel="external">
          "Yersiniosis: Infection due to Yersinia enterocolitica and Yersinia pseudotuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H525115511">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plague is a murine zoonosis; humans are incidental hosts. Humans acquire plague via bites of rodent fleas, scratches or bites from infected domestic cats, direct handling of infected animal tissues, inhalation of respiratory secretions from infected animals, inhalation of aerosolized droplets from infected humans, consumption of contaminated food, or by laboratory exposure [
         <a href="#rid1">
          1-5
         </a>
         ]. The incubation period is generally two to eight days. (See
         <a class="medical medical_review" href="/z/d/html/3143.html" rel="external">
          "Epidemiology, microbiology and pathogenesis of plague (
          <i>
           Yersinia pestis
          </i>
          infection)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three major clinical syndromes associated with plague: bubonic plague, septicemic plague, and pneumonic plague [
         <a href="#rid1">
          1
         </a>
         ]. Bubonic plague accounts for 80 to 95 percent of cases; septicemic plague accounts for 10 to 20 percent of cases [
         <a href="#rid1">
          1,6
         </a>
         ]. Pneumonic plague is generally rare [
         <a href="#rid7">
          7
         </a>
         ]. Overall, the estimated mortality is 60 to 100 percent in untreated plague compared with less than 15 percent with treatment [
         <a href="#rid8">
          8
         </a>
         ]. In a series of 23 cases of plague in the United States between 1977 and 1998, 17 were bubonic plague and the mortality rate was 22 percent [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Bubonic plague
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bubonic plague is the most common form of plague; it accounts for 80 to 95 percent of cases. Skin lesions at the site of flea bite are usually inapparent and thus ignored or forgotten. However, some patients may have eschars, pustules, or even necrotic lesions resembling ecthyma gangrenosum [
         <a href="#rid10">
          10
         </a>
         ]. Flea bites on the extremities may be associated with lymph nodes swellings in the region draining the inoculation site. A minority of patients develop skin lesions, such as purpura, associated with disseminated intravascular coagulation [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Bubonic plague is clinically characterized by the sudden onset of fever, chills, weakness, and headache, followed by intense pain and swelling in a lymph node-bearing area (bubo), which may be preceded by lymphadenopathy. Acute buboes are painful but lack fluctuation. They are often associated with erythema and edema of the overlying skin. The inguinal region is the most frequently involved site (the word "bubo" derives from the Greek word for "groin"); axillary or cervical regions may also be involved  (
         <a class="graphic graphic_picture graphicRef52633" href="/z/d/graphic/52633.html" rel="external">
          picture 1
         </a>
         ). Axillary, cervical, or epitrochlear buboes may occur in patients with bubonic plague associated with cat exposure [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         In the absence of treatment, the initial bubonic stage may be followed by disseminated infection (sepsis) in approximately 50 percent of untreated cases, which can lead to complications, such as pneumonia (secondary pneumonic plague) and meningitis [
         <a href="#rid12">
          12
         </a>
         ]. Bacteremic patients may develop signs of septic shock [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Septicemic plague
         </span>
         <span class="headingEndMark">
          —
         </span>
         Septicemic plague that occurs without a preceding bubo accounts for 10 to 20 percent of cases [
         <a href="#rid1">
          1
         </a>
         ]. The septicemic form of plague may be particularly difficult to diagnose in a timely manner if characteristic clinical clues, such as a bubo, are not present. Patients with septicemic plague are febrile and extremely ill but may not have localizing signs or symptoms. Gastrointestinal symptoms, including nausea, vomiting, diarrhea and abdominal pain, may be observed. Hypotension, disseminated intravascular coagulation, and multiorgan failure develop in the later stages of the illness.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Pneumonic plague
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumonic plague can be primary or secondary. Primary pneumonic plague can be acquired by inhalation of respiratory secretions or aerosolized droplets from infected animals or humans, or by laboratory exposure [
         <a href="#rid2">
          2-4,11,13
         </a>
         ]. Secondary pneumonic plague is more common and arises via hematogenous spread of bacteria from a bubo or other source.
        </p>
        <p>
         Primary pneumonic plague has a short incubation period, ranging from a few hours to a few days. Affected patients typically present with the sudden onset of dyspnea, high fever, pleuritic chest pain, and cough that may be accompanied by characteristic bloody sputum. Pneumonic plague is rapidly fatal unless an appropriate antimicrobial agent is begun within the first day of illness [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Secondary pneumonic plague develops in approximately 10 percent of patients with plague in the United States, usually as a result of delayed treatment of bubonic infection. The manifestations are as described above for primary pneumonic plague.
        </p>
        <p>
         Human-to-human transmission of plague via aerosols remains a source of controversy. In one study of an outbreak in Madagascar, 8 percent of 154 contacts became infected with
         <em>
          Y. pestis
         </em>
         [
         <a href="#rid7">
          7
         </a>
         ]. However, in a study of cases of plague from an outbreak in Uganda, transmission was observed only in very close contacts (caregivers) of patients who are severely ill [
         <a href="#rid14">
          14
         </a>
         ]. Treatment of patients and prophylaxis of contacts stopped the outbreak in Madagascar cited above. The capacity for spread via aerosolization makes
         <em>
          Y. pestis
         </em>
         a potential bioterrorism agent. (See
         <a class="local">
          'Prevention'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Meningitis can occur in conjunction with any of the three forms of plague, or it may occur as a "primary" meningeal infection, presumably the result of occult bacteremic seeding of the central nervous system. Symptoms tend to be similar to other bacterial meningitides. Cerebrospinal fluid examination typically reveals a low glucose concentration, increased protein concentration, and a neutrophilic pleocytosis. (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults"
         </a>
         .)
        </p>
        <p>
         Other, less common manifestations of plague include pharyngitis and tonsillitis associated with anterior cervical lymphadenitis, following ingestion of
         <em>
          Y. pestis
         </em>
         [
         <a href="#rid3">
          3,11
         </a>
         ]. Asymptomatic transient pharyngeal carriage of
         <em>
          Y. pestis
         </em>
         has been described in healthy contacts of bubonic plague cases [
         <a href="#rid15">
          15
         </a>
         ]. One small series described involvement of the urinary tract or gastrointestinal tract in 14 percent of cases [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Patients who develop plague without a bubo are difficult to diagnose, particularly when infections occur as sporadic cases in the absence of a recognized outbreak. Such patients may develop manifestations of multiple organ dysfunction and die prior to or in spite of a correct antemortem diagnosis.
        </p>
        <p class="headingAnchor" id="H2491475">
         <span class="h2">
          Laboratory and imaging features
         </span>
         <span class="headingEndMark">
          —
         </span>
         White blood cell counts may vary from 3000 to 100,000/microL, but white cell counts &gt;20,000/microL and/or thrombocytopenia are present in approximately one-half of all cases. The combination of white cell counts &gt;20,000/microL and thrombocytopenia is a useful diagnostic clue for the recognition of plague in endemic areas [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The radiographic appearance of pneumonic plague is not sufficiently specific to be diagnostic. Chest radiography may demonstrate bronchopneumonia, consolidation, cavities, or pleural effusions. Unlike other, more common bacterial pneumonias, hilar or mediastinal adenopathy is sometimes seen in patients with plague pneumonia, and this finding may provide one clue to the presence of this unusual pathogen [
         <a href="#rid17">
          17
         </a>
         ]. The sputum may initially be clear, but it is more typically purulent, or hemorrhagic, and it usually contains gram-negative rods when Gram stains are done.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H276307205">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         A high index of suspicion must be maintained in order to make a timely diagnosis of plague. Patients with fever and painful lymphadenopathy should be questioned about travel to areas of endemic disease, including the Southwestern United States. In addition, animal or rodent vector contact within the preceding 10 days may provide clues that raise suspicion for a diagnosis of plague. The diagnosis of plague is established by isolation of the organism in culture or by serologic testing [
         <a href="#rid1">
          1,2
         </a>
         ]. Occasionally, patients with plague may be coinfected with malaria, leading to diagnostic confusion in areas where malaria is endemic [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Three important diagnostic clues to the presence of plague include [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of fever in a person with either known contact with dead rodents or residence or travel to a plague-endemic region
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of fever, hypotension, and unexplained regional lymphadenitis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of clinical findings of pneumonia in association with hemoptysis and sputum containing gram-negative rods on Gram stain
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H997077138">
         <span class="h2">
          Microbiologic diagnosis
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Culture and staining
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Yersinia
         </em>
         grows well on common laboratory media. Microbiology personnel should be informed of any specimen suspected to harbor the organism so that they may exercise proper precautions to prevent laboratory acquisition of infection.
        </p>
        <p>
         Blood cultures may be positive in 27 to 96 percent of patients, depending on the form of their clinical presentation [
         <a href="#rid4">
          4,11
         </a>
         ].
         <em>
          Y. pestis
         </em>
         can also be cultured from sputum, cerebrospinal fluid, or pus aspirated from buboes. In one study, cultures of bubo aspirates were positive in 10 of 13 cases [
         <a href="#rid3">
          3
         </a>
         ]. Aspiration of the bubo after injection with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         may be necessary to obtain an adequate specimen.
        </p>
        <p>
         Examination of a peripheral blood specimen with Wright-Giemsa stain demonstrates rod-shaped organisms in up to 40 percent of cases. Microscopy evaluation of a bubo aspirate may also demonstrate the organism. Wayson stain may demonstrate the typical bipolar staining, which resembles a "closed safety pin"  (
         <a class="graphic graphic_picture graphicRef81633" href="/z/d/graphic/81633.html" rel="external">
          picture 2
         </a>
         ). Gram stain shows small gram-negative coccobacilli. Fluorescent antibody is also useful if available.
        </p>
        <p>
         Automated bacterial identification systems may not be sufficiently accurate in identifying
         <em>
          Y. pestis
         </em>
         in a specimen culture, as illustrated by reports of misclassification as
         <em>
          Pseudomonas luteola
         </em>
         ,
         <em>
          Acinetobacter lwoffi
         </em>
         , and
         <em>
          Yersinia pseudotuberculosis
         </em>
         [
         <a href="#rid19">
          19,20
         </a>
         ]. Thus, in a patient with symptoms consistent with plague or microbiologic findings of an organism with bipolar staining, the possibility of
         <em>
          Y. pestis
         </em>
         should not be discounted if these other organisms are detected by such systems.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Serology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serologic confirmation requires acute and convalescent serum, looking for at least a fourfold rise in antibody titers to the F-1 antigen of
         <em>
          Y. pestis
         </em>
         [
         <a href="#rid2">
          2
         </a>
         ]. A single titer of &gt;1:16 using the passive hemagglutination test is suggestive of the diagnosis [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Rapid tests (if available)
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rapid diagnostic test capable of detecting 0.5 ng/mL of the
         <em>
          Y. pestis
         </em>
         F1 antigen in the sputum or serum within 15 minutes has been developed [
         <a href="#rid7">
          7,21
         </a>
         ]. In field testing in Madagascar, this assay had 100 percent sensitivity and specificity for
         <em>
          Y. pestis
         </em>
         , other
         <em>
          Yersinia
         </em>
         spp, and other bacteria; positive and negative predictive values were 91 and 87 percent, respectively [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Presumptive identification of
         <em>
          Y. pestis
         </em>
         can be made by polymerase chain reaction (PCR) or antigen-capture enzyme-linked immunosorbent assay [
         <a href="#rid22">
          22,23
         </a>
         ]. PCR testing has been used to detect
         <em>
          Y. pestis
         </em>
         in teeth of skeletons that are hundreds of years old, and whole-genome sequencing of
         <em>
          Y. pestis
         </em>
         has been accomplished using specimens from victims of the Black Death who died in the Middle Ages [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         An experimental method of rapid detection and simultaneous antibiotic susceptibility testing is based upon a genetically engineered "light-tagged" reporter phage that preferentially infects
         <em>
          Y. pestis
         </em>
         and, in doing so, creates a bioluminescent signal [
         <a href="#rid25">
          25
         </a>
         ]. Because non-pestis strains of
         <em>
          Yersinia
         </em>
         and a few species of Enterobacteriaceae may also produce bioluminescence, albeit at an attenuated level, the potential for false-positive tests requires additional confirmatory tests, such as the
         <em>
          Y. pestis
         </em>
         F1 antigen. However, thus far, organisms likely to produce a plague-like illness, such as
         <em>
          Francisella tularensis
         </em>
         ,
         <em>
          Bacillus anthracis
         </em>
         , and
         <em>
          Klebsiella pneumoniae
         </em>
         , do not appear to produce false-positive tests with this method. Thus, the use of reporter phages for detection of
         <em>
          Y. pestis
         </em>
         may have utility in patients with pneumonic plague or in circumstances in which bioterrorism is suspected.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2676913311">
         <span class="h2">
          General principles
         </span>
        </p>
        <p class="headingAnchor" id="H2571840629">
         <span class="h3">
          Importance of prompt therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate and timely antibiotic therapy markedly improves patient outcomes. Delayed antibiotic therapy of plague has been associated with higher mortality. As an example, in a systematic review of 762 published cases of plague, mortality rates were higher among those treated three or more days after symptom onset than those treated within two days: 24 versus 9 percent for bubonic plague, 33 versus 20 percent for pneumonic plague, and 56 versus 18 percent for septicemic plague [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H470870129">
         <span class="h3">
          Antibiotic resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-resistant isolates of
         <em>
          Y. pestis
         </em>
         have been described but do not appear to be widely prevalent [
         <a href="#rid27">
          27-29
         </a>
         ]. Nevertheless, modification of empiric therapy may be required to conform to local susceptibility patterns.
        </p>
        <p>
         In 1995, an isolate from a patient in Madagascar contained a plasmid that conferred resistance to
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         , kanamycin,
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         , spectinomycin, sulfonamides,
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. The isolate remained sensitive to other aminoglycosides, quinolones, and
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         . The plasmid probably originated among Enterobacteriaceae and was readily passed in vitro between
         <em>
          Y. pestis
         </em>
         strains. A second isolate of
         <em>
          Y. pestis
         </em>
         with plasmid-mediated high-level streptomycin resistance was subsequently described in another patient in Madagascar, but this strain was not simultaneously resistant to other common antimicrobial agents [
         <a href="#rid31">
          31,32
         </a>
         ]. A third isolate with plasmid-mediated
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         resistance was isolated from a rat in Madagascar in 1998 [
         <a href="#rid28">
          28
         </a>
         ]. These three antibiotic-resistance plasmids were unrelated and separated in space and time, suggesting the potential for acquired antibiotic resistance under natural conditions, possibly via horizontal conjugative genetic exchange in the midgut of fleas [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2530976708">
         <span class="h2">
          Preferred antibiotic regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to regimen selection depends in part on the clinical syndrome and whether the infection is related to bioterrorism, as detailed below.
        </p>
        <p>
         In 2021, the United States Centers for Disease Control and Prevention (CDC) published guidelines on the treatment of plague. Our approach is generally consistent with those guidelines [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H603229673">
         <span class="h3">
          Bubonic plague
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with known or suspected bubonic plague, we suggest treating with an aminoglycoside (
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ), a fluoroquinolone (
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ), or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         . These are all first-line agents suggested by the CDC [
         <a href="#rid34">
          34
         </a>
         ]; doses are listed in the table  (
         <a class="graphic graphic_table graphicRef132337" href="/z/d/graphic/132337.html" rel="external">
          table 1
         </a>
         ). Of the first-line options, we generally favor an aminoglycoside, as clinical experience is greatest with this class, unless there are concerns for toxicity (eg, advanced age, chronic kidney disease, use of other nephrotoxic agents). Buboes that suppurate and become fluctuant also warrant incision and drainage.
        </p>
        <p>
         Monotherapy with one of the agents listed above is typically sufficient for naturally acquired bubonic plague, as resistance is uncommon in this setting. If infection in the setting of a bioterrorist attack is suspected, we suggest use of a combination of agents from two of the above classes until susceptibility testing results are available, consistent with CDC recommendations, because of the possibility of engineered resistance [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Patients who initially have bubonic plague but develop pulmonary involvement or disseminated disease should be treated as having pneumonic or septicemic plague. (See
         <a class="local">
          'Septicemic or pneumonic plague'
         </a>
         below.)
        </p>
        <p>
         Untreated bubonic plague has reportedly been associated with a mortality rate of 50 to 90 percent [
         <a href="#rid1">
          1,7
         </a>
         ]. Mortality rates in patients with bubonic plague who are treated with antibiotics are considerably lower. As an example, in a 2020 systematic review of studies published since 1942 that reported aggregate data on plague outcomes with antibiotic therapy, the mortality rate was 14 percent among the approximately 2000 patients with bubonic plague [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Clinical experience is most extensive with aminoglycosides, in particular
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         [
         <a href="#rid16">
          16,36,37
         </a>
         ]. However, limited aminoglycoside availability and the associated nephro- and ototoxicity often favor using alternative agents, specifically tetracyclines or fluoroquinolones.
        </p>
        <p>
         Systematic clinical data informing the efficacy of specific antibiotics are limited, and there is no clear evidence that any one of the first-line agents or antibiotic classes is superior to the others. In one of the only randomized plague trials conducted, which included 65 patients, nearly all of whom had bubonic plague, cure or clinical improvement within seven days was similarly high with either
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (94 versus 97 percent) and there were no reported relapses [
         <a href="#rid38">
          38
         </a>
         ]. The three patients who died (two with gentamicin, one with doxycycline) all did so within the first day or two of therapy.
        </p>
        <p>
         Other clinical evidence is limited to observational studies and case series [
         <a href="#rid26">
          26,39,40
         </a>
         ]. In a 2020 systematic review of published individual plague cases since 1937 that included 476 cases of bubonic plague, mortality rates were 11 percent with aminoglycosides, 0 percent with fluoroquinolones, and 7 percent with tetracyclines [
         <a href="#rid26">
          26
         </a>
         ]. Similarly, in a review of bubonic plague cases reported in the United States between 1942 and 2018, mortality rates were 8 percent with aminoglycosides, 4 percent with fluoroquinolones, and 4 percent with tetracyclines [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1917506926">
         <span class="h3">
          Septicemic or pneumonic plague
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with known or suspected septicemic or pneumonic plague, we suggest treating with an aminoglycoside (
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ) or a fluoroquinolone (
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ). These are all first-line agents suggested by the CDC [
         <a href="#rid34">
          34
         </a>
         ]; doses are listed in the table  (
         <a class="graphic graphic_table graphicRef132337" href="/z/d/graphic/132337.html" rel="external">
          table 1
         </a>
         ). Of the first-line options, we generally favor an aminoglycoside, as clinical experience is greatest with this class, unless there are concerns for toxicity (eg, advanced age, chronic kidney disease, use of other nephrotoxic agents). Levofloxacin or moxifloxacin may also be preferred in settings in which community-acquired pneumonia due to other pathogens has not been ruled out.
        </p>
        <p>
         We do not routinely use more than one drug to treat naturally acquired septicemic or pneumonic plague, as resistance in this setting is uncommon. However, the CDC suggests using agents from two different classes for patients with severe disease until the patient has clinically improved [
         <a href="#rid34">
          34
         </a>
         ]. If infection in the setting of a bioterrorist attack is suspected, we do suggest use of a combination of agents from two of the above classes until susceptibility testing results are available, consistent with CDC recommendations, because of the possibility of engineered resistance.
        </p>
        <p>
         Untreated pneumonic plague has reportedly been associated with universal mortality [
         <a href="#rid1">
          1,7
         </a>
         ], whereas the mortality rates reported for treated pneumonic and septicemic plague are much lower. As an example, in a 2020 systematic review of studies published since 1942 that reported aggregate data on plague outcomes with antibiotic therapy, the mortality rate was 31 percent among the 122 patients with pneumonic plague and 20 percent among the 10 patients with septicemic plague [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         As with bubonic plague, clinical experience is most extensive with aminoglycosides, in particular
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         [
         <a href="#rid16">
          16,36,37
         </a>
         ]. In general, clinical evidence is limited to observational studies and case series [
         <a href="#rid26">
          26,39-42
         </a>
         ]. In a 2020 systematic review of published individual plague cases since 1937, mortality rates among the 158 patients with pneumonic plague were largely similar for aminoglycosides (19 percent), fluoroquinolones (20 percent), and tetracyclines (17 percent) when each was used as monotherapy [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Tetracyclines (eg,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) are not considered first-line for septicemic or pneumonic plague since some data among nonhuman primates suggested that they were less effective than other first-line options [
         <a href="#rid43">
          43
         </a>
         ]. Nonhuman primate studies have also been used to support use of fluoroquinolones [
         <a href="#rid44">
          44,45
         </a>
         ]. As an example, in a randomized trial of African green monkeys exposed to aerosolized
         <em>
          Y. pestis
         </em>
         , 16 of 17 treated with
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         survived, whereas all of the seven control animals died [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29926102">
         <span class="h3">
          Other infections and special populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other manifestations of plague less common than bubonic, pneumonic, and septicemic plague include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharyngeal and tonsillar plague – These are treated with the same approach as bubonic plague. (See
         <a class="local">
          'Bubonic plague'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meningitis – For initial treatment of patients with plague accompanied by signs of meningitis, the CDC recommends combination therapy with
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         and
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. These agents are preferred because of higher penetration into the cerebrospinal fluid.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection during pregnancy – The CDC recommends combination therapy with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and either
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         for pregnant individuals with plague because of the high potential for maternal morbidity, possibility of perinatal transmission, and potential for increased drug clearance during pregnancy. Administration of these agents during pregnancy may warrant higher-than-usual doses.
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          Streptomycin
         </a>
         is contraindicated during pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Alternative options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative options for plague treatment include
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         . These have been effective for plague in case series and observational studies but have some drawbacks compared with the preferred agents discussed above. Other agents from the same antibiotic classes as the preferred agents (eg, aminoglycosides [
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         ], fluoroquinolones [
         <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">
          gemifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         ], tetracyclines [
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">
          omadacycline
         </a>
         ]) may also be reasonable alternatives, although clinical data with these are lacking.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          Tetracycline
         </a>
         – Mortality rates of approximately 7 to 10 percent have been reported in patients with plague treated with tetracyclines [
         <a href="#rid26">
          26
         </a>
         ]. Tetracycline, however, does not provide added benefit over
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         and is not as well tolerated. It is also not available in an intravenous formulation, so it is generally not used for initial treatment of pneumonic or septicemic plague. The dose is 500 mg orally every six hours for adults and 10 mg/kg (maximum 500 mg per dose) every six hours for children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          Chloramphenicol
         </a>
         – Mortality rates of approximately 11 to 20 percent have been reported in patients with plague treated with chloramphenicol [
         <a href="#rid26">
          26
         </a>
         ]. It achieves excellent spinal fluid penetration and may be used for treatment of meningitis either alone or in combination with an aminoglycoside [
         <a href="#rid46">
          46
         </a>
         ]. However, availability of chloramphenicol is limited in many settings, and it is associated with hematologic toxicity. The typical dose of chloramphenicol is 12.5 mg/kg intravenously every six hours [
         <a href="#rid34">
          34
         </a>
         ]. A higher dose up to 25 mg/kg (max 1 g/dose) can be given for severe infections but should be reduced with clinical improvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         – Mortality rates of approximately 21 to 23 percent have been reported in patients with plague treated with sulfonamides [
         <a href="#rid26">
          26
         </a>
         ]. Responses may be delayed or incomplete compared with other agents [
         <a href="#rid47">
          47
         </a>
         ]. The dose is 5 mg/kg of the
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         component intravenously or orally every eight hours [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Penicillins, cephalosporins, and macrolides are not appropriate agents for treatment of plague.
        </p>
        <p class="headingAnchor" id="H2348585815">
         <span class="h2">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of antimicrobial treatment for plague is uncertain; regimens are generally given for at least 7 to 14 days and for at least a few days after clinical signs and symptoms of infection have resolved. The CDC recommends at least 10 to 14 days of therapy [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Most of the limited data on plague treatment have evaluated antimicrobial regimens of 7- to 10-day duration [
         <a href="#rid38">
          38,42
         </a>
         ]. Because they are bacteriostatic agents, it is reasonable to extend
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         courses to 10 to 14 days.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H3362766446">
         <span class="h2">
          Reducing exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reducing exposure is the best preventive measure. In known endemic areas, handling sick or dead animals (including rodent carcasses) should be avoided (or if unavoidable, gloves should be worn). Close contact with individuals with suspected or diagnosed pneumonic plague should be also avoided. Other preventative measures include rodent control, flea control, and use of insect repellents. (See
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         .)
        </p>
        <p>
         International travelers to areas where plague is endemic or where an epidemic is ongoing are generally at low risk for infection, but they should take the same precautions about reducing potential exposure.
        </p>
        <p class="headingAnchor" id="H1043868514">
         <span class="h2">
          Infection control in health care settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients suspected of having any form of plague should be placed on droplet precautions until pneumonia has been ruled out and sputum cultures are negative. For individuals with pneumonic plague, droplet precautions should be continued until antibiotic therapy has been given for at least 48 hours and there is evidence of clinical improvement. Airborne precautions are typically not necessary but are reasonable during aerosol-generating procedures in patients with pneumonic plague.
        </p>
        <p>
         Otherwise, standard precautions are sufficient. Mask, eye protection, and a face shield are suggested for any procedure that could result in splashes of body fluids.
        </p>
        <p>
         In crisis settings where personal protective equipment is not available, pre-exposure prophylaxis with antimicrobials may be reasonable for health care providers and first responders if supplies are sufficient.
        </p>
        <p class="headingAnchor" id="H2846271757">
         <span class="h2">
          Post-exposure prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest post-exposure prophylaxis for individuals with unprotected face-to-face contact (ie, within one to two meters) of patients with known or suspected pneumonic plague who have not received at least 48 hours of effective antimicrobial therapy [
         <a href="#rid1">
          1
         </a>
         ]. Agents that can be used for post-exposure prophylaxis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         100 mg orally twice daily (children: 2.2 mg/kg twice daily, maximum 100 mg per dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         500 to 750 mg orally twice daily (children: 15 mg/kg twice daily, maximum 750 mg per dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         500 to 750 mg orally once daily (children &lt;50 kg: 8 mg/kg twice daily, maximum 250 mg per dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         400 mg orally once daily (for children, moxifloxacin dose depends on age)
        </p>
        <p>
        </p>
        <p>
         Post-exposure prophylaxis is generally given for seven days.
        </p>
        <p>
         There are no data informing the benefit of post-exposure prophylaxis for plague. The rationale for administration is the high mortality rates associated with pneumonic and septicemic plague and the possibility of aerosol transmission. Antibiotic options are based on evidence on the treatment of plague.
        </p>
        <p class="headingAnchor" id="H1077473744">
         <span class="h2">
          Investigational vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         A killed whole-cell vaccine has been developed but is no longer commercially available in the United States. Data on the efficacy of the vaccine are limited; much of the experience has been with vaccination of military personnel deployed to areas endemic for plague, such as Vietnam [
         <a href="#rid32">
          32
         </a>
         ]. The vaccination consists of a primary series of two injections one to three months apart, followed by a booster every six months for the duration of exposure [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The concern about plague as a bioterrorism agent has led to the development of a number of newer vaccines, some of which are undergoing clinical testing [
         <a href="#rid1">
          1,48,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H189111931">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/132501.html" rel="external">
          "Society guideline links: Plague"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2492226">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical syndromes
         </strong>
         – The three major syndromes associated with plague are bubonic plague (80 to 95 percent of cases), septicemic plague (10 to 20 percent of cases), and pneumonic plague (rare):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bubonic plague is characterized by sudden onset of fever, chills, weakness, and headache, followed by intense pain and swelling in a lymph node-bearing area (bubo). The acute bubo is exquisitely tender without fluctuation and often associated with erythema and edema  (
         <a class="graphic graphic_picture graphicRef52633" href="/z/d/graphic/52633.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="local">
          'Bubonic plague'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Septicemic plague manifests as fever and severe systemic illness without localizing signs or symptoms. Nausea, vomiting, diarrhea, and abdominal pain may occur. Hypotension, disseminated intravascular coagulation, and multiorgan failure develop in the later stages of the illness if untreated. (See
         <a class="local">
          'Septicemic plague'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pneumonic plague presents as a rapidly progressive pneumonia, with fever, chest pain, cough, and dyspnea. It can be primary (eg, acquired by inhalation of respiratory secretions or aerosolized droplets from infected animals or humans or by laboratory exposure) or secondary (eg, developing in the setting of bubonic or septicemic plague). (See
         <a class="local">
          'Pneumonic plague'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of plague is established by isolation of the organism in culture, by serologic testing or by rapid testing in appropriate settings. A high index of suspicion must be maintained for the timely diagnosis of plague. Patients with fever and painful lymphadenopathy should be questioned about travel to areas of endemic disease. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Antibiotic therapy should be administered promptly for plague. Plague is associated with mortality rates of 50 to 100 percent without treatment and 15 to 30 percent with treatment. Delay in antibiotic administration is associated with higher mortality. (See
         <a class="local">
          'Importance of prompt therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         First-line agents for plague include aminoglycosides (
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ), fluoroquinolones (
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ), and for bubonic plague,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         . For most individuals with plague, we suggest streptomycin or gentamicin (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Clinical experience is greatest with aminoglycosides, but if there are concerns about toxicity (eg, advanced age, chronic kidney disease, use of other nephrotoxic agents), limited data suggest the other first-line agents are also effective. Doses are listed in the table  (
         <a class="graphic graphic_table graphicRef132337" href="/z/d/graphic/132337.html" rel="external">
          table 1
         </a>
         ). Duration of therapy ranges from 7 to 14 days. (See
         <a class="local">
          'Preferred antibiotic regimens'
         </a>
         above and
         <a class="local">
          'Duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Monotherapy is likely sufficient for most patients with naturally acquired plague because antibiotic resistance is uncommon. However, we suggest combination therapy with two of the agents listed above for treatment of plague when a bioterrorism event is suspected or documented because of the possibility of engineered resistance (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Combination therapy is also reasonable for those with severe septicemic or pneumonic plague. (See
         <a class="local">
          'Preferred antibiotic regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control
         </strong>
         – Patients suspected of having any form of plague should be placed on droplet precautions until pneumonia has been ruled out, sputum cultures are negative, and at least 48 hours of effective antimicrobial therapy has been administered. (See
         <a class="local">
          'Infection control in health care settings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-exposure prophylaxis
         </strong>
         –
         <strong>
         </strong>
         We suggest post-exposure prophylaxis for individuals with unprotected face-to-face contact (ie, within two meters) of patients with known or suspected pneumonic plague who have not received at least 48 hours of effective antimicrobial therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Appropriate agents for prophylaxis include
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         . (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Prentice MB, Rahalison L. Plague. Lancet 2007; 369:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Human plague--United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1994; 43:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crook LD, Tempest B. Plague. A clinical review of 27 cases. Arch Intern Med 1992; 152:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weniger BG, Warren AJ, Forseth V, et al. Human bubonic plague transmitted by a domestic cat scratch. JAMA 1984; 251:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Fatal laboratory-acquired infection with an attenuated Yersinia pestis Strain--Chicago, Illinois, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daya M, Nakamura Y. Pulmonary disease from biological agents: anthrax, plague, Q fever, and tularemia. Crit Care Clin 2005; 21:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratsitorahina M, Chanteau S, Rahalison L, et al. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 2000; 355:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell GL, Hughes JM. Plague in India: a new warning from an old nemesis. Ann Intern Med 1995; 122:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gage KL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis 2000; 30:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welty TK, Grabman J, Kompare E, et al. Nineteen cases of plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in pregnancy. West J Med 1985; 142:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler T. Yersinia infections: centennial of the discovery of the plague bacillus. Clin Infect Dis 1994; 19:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren R, Lockman H, Barnewall R, et al. Cynomolgus macaque model for pneumonic plague. Microb Pathog 2011; 50:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang H, Cui Y, Wang Z, et al. A dog-associated primary pneumonic plague in Qinghai Province, China. Clin Infect Dis 2011; 52:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Begier EM, Asiki G, Anywaine Z, et al. Pneumonic plague cluster, Uganda, 2004. Emerg Infect Dis 2006; 12:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JD Jr, Quy DV, Gibson FL. Asymptomatic pharyngeal plague infection in Vietnam. Am J Trop Med Hyg 1967; 16:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler T, Bell WR, Nguyen-Ngoc-Linh, et al. Yersinia pestis infection in Vietnam. I. Clinical and hematologic aspects. J Infect Dis 1974; 129:Suppl:S78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsofrom DJ, Mettler FA Jr, Mann JM. Radiographic manifestations of plaque in New Mexico, 1975-1980. A review of 42 proved cases. Radiology 1981; 139:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinyange N, Kumar R, Inambao A, et al. Outbreak of Plague in a High Malaria Endemic Region - Nyimba District, Zambia, March-May 2015. MMWR Morb Mortal Wkly Rep 2016; 65:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourdjman M, Ibraheem M, Brett M, et al. Misidentification of Yersinia pestis by automated systems, resulting in delayed diagnoses of human plague infections--Oregon and New Mexico, 2010-2011. Clin Infect Dis 2012; 55:e58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CL, Mould K, Reynolds P, et al. Clinical problem-solving. Sick as a dog. N Engl J Med 2015; 372:1845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chanteau S, Rahalison L, Ralafiarisoa L, et al. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet 2003; 361:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loïez C, Herwegh S, Wallet F, et al. Detection of Yersinia pestis in sputum by real-time PCR. J Clin Microbiol 2003; 41:4873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radnedge L, Gamez-Chin S, McCready PM, et al. Identification of nucleotide sequences for the specific and rapid detection of Yersinia pestis. Appl Environ Microbiol 2001; 67:3759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifert L, Harbeck M, Thomas A, et al. Strategy for sensitive and specific detection of Yersinia pestis in skeletons of the black death pandemic. PLoS One 2013; 8:e75742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandamm JP, Rajanna C, Sharp NJ, et al. Rapid detection and simultaneous antibiotic susceptibility analysis of Yersinia pestis directly from clinical specimens by use of reporter phage. J Clin Microbiol 2014; 52:2998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson CA, Fleck-Derderian S, Cooley KM, et al. Antimicrobial Treatment of Human Plague: A Systematic Review of the Literature on Individual Cases, 1937-2019. Clin Infect Dis 2020; 70:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urich SK, Chalcraft L, Schriefer ME, et al. Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia. Antimicrob Agents Chemother 2012; 56:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabanel N, Bouchier C, Rajerison M, Carniel E. Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat. Int J Antimicrob Agents 2018; 51:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrianaivoarimanana V, Wagner DM, Birdsell DN, et al. Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak. Clin Infect Dis 2022; 74:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galimand M, Guiyoule A, Gerbaud G, et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997; 337:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiyoule A, Gerbaud G, Buchrieser C, et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001; 7:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavanaugh DC, Elisberg BL, Llewellyn CH, et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974; 129:Suppl:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galimand M, Carniel E, Courvalin P. Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother 2006; 50:3233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. Clin Infect Dis 2020; 70:S11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagle PM. Recent advances in the treatment of bubonic plague. Indian J Med Sci 1948; 2:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MEYER KF. Modern therapy of plague. J Am Med Assoc 1950; 144:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mwengee W, Butler T, Mgema S, et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 2006; 42:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulanger LL, Ettestad P, Fogarty JD, et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. Clin Infect Dis 2004; 38:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugeler KJ, Mead PS, Campbell SB, Nelson CA. Antimicrobial Treatment Patterns and Illness Outcome Among United States Patients With Plague, 1942-2018. Clin Infect Dis 2020; 70:S20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuberski T, Robinson L, Schurgin A. A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. Clin Infect Dis 2003; 36:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apangu T, Griffith K, Abaru J, et al. Successful Treatment of Human Plague with Oral Ciprofloxacin. Emerg Infect Dis 2017; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hewitt JA, Lanning LL, Campbell JL. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule. Clin Infect Dis 2020; 70:S51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Layton RC, Mega W, McDonald JD, et al. Levofloxacin cures experimental pneumonic plague in African green monkeys. PLoS Negl Trop Dis 2011; 5:e959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson JW, Moen ST, Healy D, et al. Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Open Microbiol J 2010; 4:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MCCRUMB FR Jr, MERCIER S, ROBIC J, et al. Chloramphenicol and terramycin in the treatment of pneumonic plague. Am J Med 1953; 14:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen-Van-Ai, Nguyen-Duc-Hanh, Pham-Van-Dien, Nguyen-Van-Le . Letter: Co-trimoxazole in bubonic plague. Br Med J 1973; 4:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris SR. Development of a recombinant vaccine against aerosolized plague. Vaccine 2007; 25:3115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demeure CE, Derbise A, Carniel E. Oral vaccination against plague using Yersinia pseudotuberculosis. Chem Biol Interact 2017; 267:89.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3131 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17416264" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8145715" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Human plague--United States, 1993-1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1599354" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Plague. A clinical review of 27 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6694293" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Human bubonic plague transmitted by a domestic cat scratch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346706" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Fatal laboratory-acquired infection with an attenuated Yersinia pestis Strain--Chicago, Illinois, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16168313" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pulmonary disease from biological agents: anthrax, plague, Q fever, and tularemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10675169" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7992992" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Plague in India: a new warning from an old nemesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10852811" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cases of cat-associated human plague in the Western US, 1977-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4013279" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nineteen cases of plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7803628" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Yersinia infections: centennial of the discovery of the plague bacillus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040776" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cynomolgus macaque model for pneumonic plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21288842" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A dog-associated primary pneumonic plague in Qinghai Province, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16704785" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pneumonic plague cluster, Uganda, 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6021740" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Asymptomatic pharyngeal plague infection in Vietnam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4825250" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Yersinia pestis infection in Vietnam. I. Clinical and hematologic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7232721" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Radiographic manifestations of plaque in New Mexico, 1975-1980. A review of 42 proved cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513350" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Outbreak of Plague in a High Malaria Endemic Region - Nyimba District, Zambia, March-May 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22715170" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Misidentification of Yersinia pestis by automated systems, resulting in delayed diagnoses of human plague infections--Oregon and New Mexico, 2010-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25946284" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical problem-solving. Sick as a dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12547544" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Development and testing of a rapid diagnostic test for bubonic and pneumonic plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14532247" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Detection of Yersinia pestis in sputum by real-time PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11472963" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Identification of nucleotide sequences for the specific and rapid detection of Yersinia pestis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24069445" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Strategy for sensitive and specific detection of Yersinia pestis in skeletons of the black death pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920765" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rapid detection and simultaneous antibiotic susceptibility analysis of Yersinia pestis directly from clinical specimens by use of reporter phage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32435802" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Antimicrobial Treatment of Human Plague: A Systematic Review of the Literature on Individual Cases, 1937-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22024826" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29030266" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34244722" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278464" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11266293" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4596518" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Plague immunization. V. Indirect evidence for the efficacy of plague vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005799" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Resistance of Yersinia pestis to antimicrobial agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34264565" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32435800" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recent advances in the treatment of bubonic plague
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14774219" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Modern therapy of plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16447105" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14986250" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32435801" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antimicrobial Treatment Patterns and Illness Outcome Among United States Patients With Plague, 1942-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12567312" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28125398" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Successful Treatment of Human Plague with Oral Ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32435803" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21347450" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Levofloxacin cures experimental pneumonic plague in African green monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21127743" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13030486" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chloramphenicol and terramycin in the treatment of pneumonic plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4745331" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Letter: Co-trimoxazole in bubonic plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17291640" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Development of a recombinant vaccine against aerosolized plague.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27046452" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Oral vaccination against plague using Yersinia pseudotuberculosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
